trial the use of drugs which depress hypothalamic activity, and are thereby likely to enhance prolactin secretion (tranquillizers and antihypertensive drugs, such as reserpine derivatives), was strictly prohibited. Because pyridoxine antagonizes the effects of L-dopa vitamin preparations containing this compound were not allowed. Only salicylates and local irradition were allowed for control of pain and only barbiturates as sedatives. Patients with severe pain that might not be controlled effectively by these measures were excluded from the study.
L-Dopa was given by mouth, starting with a daily dose of 750 mg divided in three 250-mg doses taken with meals. After one week a daily dose of 1500 mg was given in three 500-mg doses. This dose was the same as that reported in other papers for the same therapeutic use. i Dopa treatment was to be discontinued if the disease remained progressive, it was to be given for at least six weeks if the disease remained unchanged, and was to be continued if regression occurred. Nafoxidine 60 mg three times a day was given orally.
Results
Originally 49 patients were entered into each treatment group. After review of all the patients' records 76 patients were considered evaluable, 36 in the nafoxidine group and 40 in the L-dopa group. The 22 patients excluded consisted of five on nafoxidine who died within a week of starting the trial, one on each drug who had central nervous system involvement, two on each drug who were lost to follow-up, three osi nafoxidine and five on L-dopa who had been castrated less than two years before, and two on nafoxidine and one on L-dopa who had other hormones added.
There were differences between the two treatment groups (see table) : the disease-free interval was significantly shorter in the nafoxidine-treated patients (P = 0 006; Mantel-Haenszel test) and visceral metastases predominated in the L-dopa group, though not significantly (P = 0 08). These differences would tend to favour L-dopa.
Objective remissions occurred in seven out of 36 patients (19%) on nafoxidine. Remission lasted a mean of nine months (median seven months). No objective remissions were obtained with L-dopa. In those in whom treatment failed both treatments had lasted for a mean of six weeks, with a median of 7 6 weeks in the nafoxidine group and 7-5 weeks in the L-dopa group. The difference in effectiveness between the two drugs was highly significant (P<0 01; Fisher's exact probability test, two-sided).
Side effects ascribed to the drugs were seen in about half the patients. Nausea and vomiting were frequent complaints with L-dopa (15 cases); with nafoxidine skin changes were the major cause of complaints. Phototoxicity was most prominent in patients in remission on nafoxidine treatment (six cases) who had been given the drug for prolonged periods.
Discussion
Our results show that no objective remission was obtained in a group of 40 patients with advanced breast cancer treated with oral L-dopa. The 19% remission rate in the control group treated with nafoxidine shows that our patient population was not unusual and responded normally to an endocrine-related compound of known efficacy.
L-Dopa's failure to achieve objective remissions in patients with breast cancer was not unexpected but seemed worth being firmly established in view of reported claims to the contrary (see Introduction). Our results seem to settle the question because our study covered a substantial number of patients whereas other series were small and patients' responses were not reviewed independently. To our knowledge these small series have not been expanded and in at least one of them no new% remission has been obtained. '8 We did not expect to obtain remissions from L-dopa because it is a poor inhibitor of prolactin secretion. Rozencweig et al.1' showed that L-dopa produced a saw-tooth effect on blood prolactin levels, with decreases followed by large rebounds. Bromocriptine (CB 154), however, steadily depressed the blood prolactin level down to 250% of the pretreatment level in postmenopausal women.'0 Yet bromocriptine also failed tc produce a single case of remission of breast cancer. ' 
